From Inactive Ingredients to Pharmaceutical Excipients

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2001
Volume 25
Issue 7

Developments in technology and increased industry standards have changed the regulation, quality control, and perception of excipients in the past 25 years.

External Link - article-5533.pdf

Articles in this issue
Musings on the Past 25 Years
Reflections on Changes at FDA
Deliver the Dose
Middle-European Pharmaceutics in a Changing World
The BCS: Where Do We Go From Here?
The Role of USP in the Assessment of Microbiological Quality of Pharmaceuticals
From Inactive Ingredients to Pharmaceutical Excipients
Am I Going Backwards?
The Filter Scene: Old and New
Catching Up with Expert Systems
25 Years of Change in the Parenteral Technology Field
The Future State of Computer Validation, Part I
Statistical Thinking
2001: An Odyssey in Inhaler Formulation and Design
What Is the "Correct" Method to Use for Particle-Size Determination?
Recent Videos
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Incyte, Genesis Therapeutics to Use AI Platform to Discover Small Molecule Compounds

Patrick Lavery
February 21st 2025
Article

The collaboration will utilize Genesis’ proprietary AI platform, initially focusing on targets selected by Incyte.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Google Launches AI Co-Scientist System

Susan Haigney
February 20th 2025
Article

The AI co-scientist is a multi-agent AI system that can work as a virtual scientific collaborator.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

MMS Acquires Exploristics and Its Flagship Modeling and Simulation Platform

Patrick Lavery
February 14th 2025
Article

In seeking a data-driven approach to efficient drug development, MMS aims to enhance its capabilities in advanced clinical trial design, innovative statistics, and data science with the acquisition.

Young female tech or scientist performs protein assay | Image Credit: © tilialucida - stock.adobe.com

Leaving STEM Skills on the Table

Susan Haigney
February 13th 2025
Article

Investing in STEM programs for girls in an education setting and then supporting women as they excel in their professional careers is key to ensuring that vital highly skilled personnel are not left behind.